<DOC>
	<DOCNO>NCT02736175</DOCNO>
	<brief_summary>To evaluate safety efficacy OTX-DP sustain release drug ( dexamethasone ) depot place canaliculus eyelid treatment post-surgical inflammation pain subject undergone cataract extraction intra-ocular lens implantation .</brief_summary>
	<brief_title>Phase 3 Study Evaluating Safety Efficacy OTX-DP Treatment Ocular Inflammation Pain After Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Capsule Opacification</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Has cataract expect undergo clear corneal cataract surgery phacoemulsification implantation posterior chamber lens Has potential postoperative pinhole correct Snellen VA least 20/200 good eye Any intraocular inflammation study eye present screen slit lamp examination Score great `` 0 '' Ocular Pain Assessment study eye Screening Any intraocular inflammation study eye present screen slit lamp examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>